Michelle focuses her practice on corporate and securities matters, such as transactions and general corporate matters. She works with companies across a variety of industries, including life sciences, medical devices, and real estate.
While earning her JD, Michelle interned with an international medical device company, where she reviewed and suggested changes for non-disclosure agreements (NDAs), marketing agreements, and sales contracts. She also conducted research on medical device law and social media influencer law. In an externship in the Real Estate Practice of a global law firm, Michelle drafted closing documents and exhibits for client purchases and researched property issues. Additionally, while working as a law clerk for a Massachusetts-based firm, she gained experience in family law and property law.
In law school, Michelle served as a negotiations competition judge, a research assistant to a professor, a 1L student mentor, and a student ambassador to the Boston Bar Association.
News & Press
Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $157.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 318,470 shares of common stock at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to Praxis Precision Medicines from this offering were approximately $603 million before deducting underwriting discounts and commissions and other offering expenses.
Recent Insights
Mintz advised the underwriters in connection with a $603 million public offering by Praxis Precision Medicines of 3,527,072 shares of common stock (which includes 501,592 shares of common stock issued pursuant to the exercise in full by the underwriters of their option to purchase additional shares of common stock) at a public offering price of $157.00 per share, and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 318,470 shares of common stock at the public offering price per share less the $0.0001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds to Praxis Precision Medicines from this offering were approximately $603 million before deducting underwriting discounts and commissions and other offering expenses.
